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Background:  Serum  uric  acid  (SUA)  has been  observed  to be highly  associated  with  the  development  of
cardiovascular  disease  for  more  than 50  years.  Several  studies  have  reported  elevated  SUA  as an  inde-
pendent  predictor  of mortality  in  patients  with  coronary  artery  disease  (CAD)  after adjustment  for classic
risk factors  but  some  studies  did not  ﬁnd  similar  results.
Methods:  Between  January  1997  and  December  2003,  a prospective  cohort  study  was  performed  in 1054
patients  with  angiographically  deﬁned  CAD,  and  their  classic  risk  factors  and  SUA  levels  were  determined
at  enrollment.  The  study  cohort  was  followed  for an  average  of 3.2 years,  with  a  median  of 3.1  years.  The
main  outcome  measure  was  death  from  cardiac  disease  and  any  cause.
Results:  Of  all  study  patients,  789  (74.9%)  were  men  and  265  (25.1%)  were  women.  The  mean  age  of  the
male  and  female  patients  was  64.8  and  66.9 years,  respectively.  The  mean  SUA  level  of  all  patients  was
410.4 mol/L.  There  were  grading  effects  of  SUA  quartiles  on  cardiac  and  all-cause  mortality  in univari-
ate and  multivariate  Cox  regression  analyses.  After  adjustment,  the multivariate  analyses  revealed  that
patients  in  the  highest  SUA  quartile  (>487  mol/L)  had  2.08  (95%  CI = 1.19–3.62,  p =  0.01)  fold  increased
risk  of cardiac  death,  and  1.68 (95%  CI =  1.10–2.57,  p =  0.017) fold  increase  risk  of  overall  mortality  com-
pared  with  the  lowest  quartile  (<315  mol/L).
Conclusions:  SUA  may  be  a  signiﬁcant  predictor  of  cardiac  and  overall  mortality,  independent  of classic
atien
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Serum uric acid (SUA) has been observed to be highly asso-
iated with the development of cardiovascular disease for more
han 50 years. Experimentally, UA has been shown to generate
minocarbonyl radicals which have proinﬂammatory and anti-
xidant effects on vascular smooth muscle cells subsequently
eading to cardiovascular disease [1–4]. In addition, UA has been
ound to have a causal role in the pathogenesis of vascular
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hypertension and atherosclerosis [5–7]. A number of reports
supported that elevated SUA could be seen as an independent
predictor of mortality in patients with coronary artery disease
(CAD) after adjustment for classic risk factors [8–15]. On the con-
trary, UA is largely produced by the vascular endothelium and
elevated SUA may  merely be a marker of endothelial dysfunc-
tion reﬂecting the condition of metabolic syndrome and insulin
resistance [16,17].  In this respect, some studies did not ﬁnd a sim-
ilar relationship between SUA and cardiovascular outcomes [18].
Accordingly, we assessed the prognostic value of SUA  levels for car-
diac and overall mortality in patients with CAD in eastern Taiwan.
A prospective cohort study was performed in 1054 angiographi-
cally deﬁned CAD patients, and their classic risk factors and SUA
levels were determined at enrollment. The study cohort was fol-
lowed for an average of 3.2 years, with a median of 3.1 years. The
main outcome measure was death from cardiac disease and any
cause.
vier Ltd. All rights reserved.
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nervous system disease (n = 1), psychosis disease (n = 1), and dis-
orders of thyroid gland (n = 1). Fig. 2 shows the Kaplan–Meier
survival without cardiac death, and Table 2 presents the cardiac
and all-cause mortalities of patients in each SUA  quartile group.
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tudy subjects
Between January 1997 and December 2003, a cohort of 1347
atients was prospectively enrolled in the registry of “the Eastern
aiwan integrated health care delivery system of Coronary Heart
isease (ET-CHD)” at Tzu-Chi General Hospital, Hualien, Taiwan. At
nrollment, all study subjects were diagnosed to have obstructive
AD based on angiographic evidence of at least one major coronary
rtery or primary branch with a diameter stenosis of ≥50%. We
xcluded 40 patients with a prior cancer, 73 patients with missing
UA data, and 180 subjects with missing data for any adjustment
ovariate at baseline. Thus, the ﬁnal sample size for this study was
054.
aboratory assessments
Blood samples were drawn from study patients at the time of
oronary angiography. The clinical chemistry was  measured by
U640e Chemistry Immuno Analyzer (AU640, Olympus, Tokyo,
apan). Each measurement used the reagents for the AU640:
UA, OSR6136, uricase method; total cholesterol, OSR6116, enzy-
atic; aminoantipyrene/phenol/peroxidase method; high-density
ipoprotein (HDL) cholesterol, OSR 6287, direct-no pretreatment
nzymatic immuno-inhibition method; triglyceride, OSR6133,
lycerol phosphate oxidase method; creatinine, OSR6178, modi-
ed Jaffe kinetic method, and urea nitrogen, OSR6234, urease/GLDH
ethod. Diabetes mellitus was diagnosed in patients with a his-
ory of antidiabetic or insulin medication or fasting blood glucose
125 mg/dL at baseline. Hypertension was diagnosed in those with
 history of antihypertensive drugs or baseline blood pressure
140/90 mmHg.
ndpoint
The survival status and cause of death were ascertained by
inkage to the mortality database until December 31, 2003. The
ortality database, submitted standardized certiﬁcates for each
eath, is mandatory for physicians by the Department of Health.
o the vital statistics published by the National Health Department
f Taiwan are almost complete, with a physician conﬁrmation rate
f 99%. This study was  approved by the local ethics committee
IRB096-39).
tatistical analysis
Study subjects were evenly classiﬁed into 4 groups according
o their SUA levels. Chi-square tests were used to test the equality
cross the four study groups for categorical variables. Since most
ontinuous variables in this study did not follow a normal distri-
ution, Kruskal–Wallis test, a nonparametric method without the
equirement of normal assumption, was used to determine the dif-
erence among the 4 study groups. Kaplan–Meier survival curves
ere plotted to depict the probabilities without cardiac death for
he study subjects over time. Cox proportional hazard regression
odels were used to determine the independent effects of SUA on
verall and cardiac mortality while adjusting for the related social
nd clinical risk factors. All statistical analyses were performed with
AS version 9.1 (SAS Institute, Cary, NC, USA). A p-value < 0.05 was
onsidered statistically signiﬁcant.esults
Of all study patients, 789 (74.9%) were men  and 265 (25.1%)
ere women. At baseline, the mean age of the study male patientsFig. 1. Baseline uric acid level by age group for male and female patients with
coronary artery disease. Data in each age-gender group are mean ± standard error.
was 64.8 ± 11.3 years and of female patients was 66.9 ± 9.0 years.
The mean SUA level of all study patients was  410.4 ± 129.1 mol/L.
The SUA level was  higher in males than in females (414.4 mol/L
vs. 362.5 mol/L, p < 0.001) for patients younger than 65 years;
there was  no signiﬁcant difference between older male patients
and female patients (410.1 mol/L vs. 422.4 mol/L, p = 0.346)
(Fig. 1). The baseline clinical characteristics according to the quar-
tile value of SUA level for the whole study population are shown
in Table 1. Those with higher SUA levels were with higher body
mass index (BMI), systolic blood pressure, serum creatinine, serum
total cholesterol, serum triglyceride, and they had more hyperlipi-
demia, gout, and obesity. Among these variables, the presence of
gout history was highly associated with higher SUA levels. At dis-
charge, aspirin was prescribed to all study patients and diuretics
were mainly used for those with heart failure or with a reduced
left ventricular ejection fraction. Therefore, diuretic use was highly
correlated to heart failure and increased with higher SUA levels.
As of December 2003, there were 195 deaths including 127
(65.1%) cardiac deaths and 68 noncardiac deaths. The 68 noncardiac
deaths were due to neoplastic disease (n = 15), cerebrovascular dis-
ease (n = 13), diabetes mellitus (n = 10), respiratory system disease
(n = 8), digestive system disease (n = 6), injury and poison (n = 5),
renal and urinary system disease (n = 5), infectious disease (n = 3),Time(months)
Fig. 2. Kaplan–Meier survival without cardiac mortality by uric acid quartile in coro-
nary artery disease patients. Log-rank test of survival differences produced a p-value
of  0.03.
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Table  1
Baseline characteristics by uric acid quartile.
Total n = 1054 Quartile 1 (<315)
n  = 265
Quartile 2 (315–395)
n = 262
Quartile 3 (395–486)
n = 258
Quartile 4 (>487)
n  = 269
p-Value
Uric acid (mol/L) 410.4 ± 129.1 258.1 ± 49.4 357.0 ± 23.3 439.4 ± 27.0 578.1 ± 84.5 <0.001
Age  (years) 65.3 ± 10.8 65.2 ± 10.3 64.6 ± 10.7 65.5 ± 10.7 66.0 ± 11.6 0.211
Male  gender (%) 74.9 68.7 78.2 76 76.6 0.056
Body  mass index (kg/m2) 25.5 ± 3.6 25.0 ± 3.4 25.6 ± 3.5 25.7 ± 3.5 25.9 ± 4.0 0.034
Systolic blood pressure (mmHg) 132.4 ± 19.9 130.5 ± 20.0 132.3 ± 18.9 134.0 ± 21.4 132.7 ± 19.2 0.048
Diastolic blood pressure (mmHg) 77.1 ± 12.2 76.9 ± 11.4 77.3 ± 11.3 77.6 ± 12.5 76.7 ± 13.5 0.746
Smoking status 0.565
Nonsmoker (%) 47.7 53.2 45.4 46.5 45.7
Exsmoker (%) 16.5 14.7 17.2 15.9 18.2
Current smoker (%) 35.8 32.1 37.4 37.6 36.1
Hypertension (%) 71.3 67.2 70.6 74.8 72.9 0.246
Hyperlipidemia (%) 43.8 31.3 46.6 47.7 49.8 <0.001
Diabetes mellitus (%) 41.3 44.9 38.9 40.3 40.9 0.542
Stroke  (%) 9.3 9.4 8.8 9.3 9.7 0.988
Gout  (%) 9.2 2.3 6.1 7.4 20.8 <0.001
Obesity (%) 32.9 26 34.7 34.5 36.4 0.049
Laboratory ﬁndings
Serum total cholesterol (mmol/L) 4.91 ± 1.19 4.64 ± 1.05 4.88 ± 1.05 5.03 ± 1.3 5.10 ± 1.24 <0.001
HDL  cholesterol (mmol/L) 1.10 ± 0.29 1.12 ± 0.29 1.10 ± 0.31 1.08 ± 0.28 1.08 ± 0.29 0.473
LDL  cholesterol (mmol/L) 2.93 ± 1.06 2.77 ± 0.92 2.93 ± 1.03 2.98 ± 1.08 3.02 ± 1.17 0.022
Serum triglyceride (mmol/L) 1.96 ± 1.34 1.65 ± 1.03 1.86 ± 1.21 2.12 ± 1.50 2.19 ± 1.50 <0.001
Creatinine (mol/L) 117.7 ± 77.9 105.31 ± 93.81 106.20 ± 38.94 118.59 ± 69.03 138.95 ± 92.04 <0.001
Fasting glucose (mmol/L) 0.80 ± 0.40 0.82 ± 0.40 0.78 ± 0.42 0.80 ± 0.40 0.80 ± 0.42 0.453
Blood  urea nitrate (mmol/L) 3.57 ± 1.72 3.12 ± 1.47 3.27 ± 1.17 3.65 ± 1.65 4.2 ± 2.2 <0.001
Clinical presentation
Number of blocked coronary arteries 0.064
Single-vessel (%) 38.3 41.1 44.7 36.1 31.6
Double-vessel (%) 21.5 19.6 18.3 24 23.8
Triple-vessel (%) 40.2 39.3 37 39.9 44.6
Angina pectoris (%)a 72.3 69.8 69.1 74.4 75.8 0.219
Myocardial infarction (%) 42.1 41.5 41.6 39.9 45.4 0.63
Treatment
PCI  (%) 53.6 53.2 55.0 53.1 53.2 0.968
CABG  (%) 24.0 24.2 20.6 22.9 28.3 0.212
Medication only (%) 25.9 26.0 27.9 29.1 20.8 0.139
Medication at enrollment
Diuretic (%)b 22.2 14.3 19.1 22.1 33.1 <0.001
Calcium channel blockers (%) 40.7 41.5 47.3 34.5 39.4 0.028
ACE  inhibitor (%) 50.1 49.4 48.5 50 52.4 0.825
Beta-blocker (%) 38.5 41.9 36.6 37.2 38.3 0.604
Statins (%) 16.9 15.9 17.9 15.1 18.6 0.673
Allopurinol (%) 2.8 3.4 1.5 2.3 3.7 0.393
HDL, high-density lipoprotein; LDL, low-density lipoprotein; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; ACE, angiotensin-converting
enzyme.
a Acute coronary syndrome, 90% in angina pectoris distributed evenly among groups.
b Diuretics were mainly used for patients with heart failure or with a reduced left ventricular ejection fraction; p-values were derived from Chi-square or Kruskal–Wallis
test.
Table  2
Relations of serum uric acid level to cardiac and all-cause mortalities.
Serum uric acid level Event (n) Rate per 1000
person-years
Relative risk (95% CI and p-value)
Unadjusted Fully adjusteda
Death from cardiac diseases
Quartile 1 (<315 mol/L) 20 23.2 1.0 1.0
Quartile 2 (315–395 mol/L) 30 34.8 1.51 (0.86–2.66) 0.154 1.39 (0.78–2.49) 0.268
Quartile 3 (395–487 mol/L) 30 36.1 1.55 (0.88–2.74) 0.127 1.46 (0.82–2.62) 0.201
Quartile 4 (>487 mol/L) 47 59.7 2.52 (1.49–4.25) <0.001 2.08 (1.19–3.62) 0.010
Death  from all causes
Quartile 1 (<315 mol/L) 37 43.0 1.0 1.0
Quartile 2 (315–395 mol/L) 40 46.5 1.09 (0.70–1.70) 0.717 1.06 (0.67–1.68) 0.797
Quartile 3 (395–487 mol/L) 53 63.7 1.48 (0.98–2.26) 0.065 1.47 (0.96–2.26) 0.080
Quartile 4 (>487 mol/L) 65 82.6 1.90 (1.27–2.85) 0.002 1.68 (1.10–2.57) 0.017
a Adjusted for age, gender, body mass index, creatinine, high-density lipoprotein cholesterol, smoking status, hypertension, diabetes, stroke, number of blocked coronary
arteries, myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, and medication status (diuretic, calcium channel blockers, angiotensin-
converting enzyme inhibitors, statins).
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Fig. 3. Kaplan–Meier survival without cardiac mortality by gender and uric acid
(UA)  group (low vs. high) in coronary artery disease patients. Female patients with
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Fig. 4. Kaplan–Meier survival without cardiac mortality by age and uric acid (UA)
T
T
High  UA had lower survival rate than the other three groups (male with low UA,
ale  with high UA, and female with low UA). p-Value < 0.001 by log-rank test.
rude all-cause mortality rates were 58.4/1000 person-years for
ll patients, 47.3 for male patients, and 96.2 for female patients.
rude cardiac mortality rates were 38.0/1000 person-years for all
atients, 29.1 for male patients, and 68.5 for female patients.
In Figs. 3 and 4, the ﬁrst two SUA quartile groups were com-
ined as a low SUA group, and the last 2 quartile groups as a high
UA group. Fig. 3 presents the survival probabilities without car-
iac death in the CAD patients by gender and SUA group. Female
atients with high SUA had signiﬁcantly lower survival rate than
he other three groups (male with low SUA, male with high SUA,
nd female with low SUA). Fig. 4 demonstrates the survival rates
y gender and age group. When controlling for age, patients with
igh SUA had consistently lower survival rate than those with low
UA.In Tables 2 and 3, multivariate Cox regression analysis was
sed to determine the independent effects of SUA on overall
nd cardiac mortality while adjusting for 20 covariates including
able 3
he hazard ratio of clinical variables in univariate and multivariate analysis of cardiac mo
Covariate Univariate analysis
HR [exp(bi)] 95% CI 
Uric acid (mg/dL) 1.16 1.08–1.25 
Age  (year) 1.06 1.04–1.09 
Female gender 2.28 1.60–3.25 
Body  mass index (kg/m2) 0.91 0.86–0.96 
Creatinine (10 mol/L) 1.02 1.00–1.03 
HDL  cholesterol (mmol/L) 0.45 0.24–0.86 
Smoking status (reference = nonsmoker)
Exsmoker 1.01 0.62–1.63 
Current smoker 0.88 0.59–1.30 
Hypertension 1.19 0.80–1.76 
Diabetes mellitus 2.07 1.46–2.95 
Stroke 2.07 1.28–3.34 
Number of blocked coronary artery (reference = single-vessel)
Double-vessel 1.53 0.89–2.64 
Triple-vessel 2.76 1.79–4.26 
Myocardial infarction 1.74 1.23–2.47 
PCI  0.73 0.52–1.04 
CABG 1.09 0.73–1.62 
Med  only 1.33 0.92–1.94 
Diuretic 3.19 2.25–4.54 
Calcium channel blockers 0.90 0.63–1.29 
ACE  inhibitor 1.12 0.79–1.59 
Beta-blocker 0.53 0.36–0.78 
Statins 0.73 0.42–1.25 
Allopurinol/probenecid 0.92 0.29–2.89 
DL, high-density lipoprotein; PCI, percutaneous coronary intervention; CABG, coronary group (low vs. high) in coronary artery disease patients. Log-rank test of survival
differences produced a p-value < 0.001.
diuretic use. There were grading effects of SUA quartiles on car-
diac and all-cause mortality in univariate and multivariate Cox
regression analyses. In Table 2, the multivariate analyses revealed
that patients in the highest SUA quartile (>487 mol/L) had 2.08
(95% CI = 1.19–3.62, p = 0.010) fold increased risk of cardiac death,
and 1.68 (95% CI = 1.10–2.57, p = 0.017) fold increased risk of over-
all mortality compared with the lowest quartile (<315 mol/L).
In separate analyses, controlling for the same 20 covariates, the
relative risk (RR) of cardiac death increased 10% (RR = 1.10, 95%
CI = 1.02–1.19, p = 0.02) (Table 3), and the RR of any cause death
increased 8% (RR = 1.08, 95% CI = 1.02–1.15, p = 0.016) (model not
shown), for each 59.48 mol/L (=1 mg/dL) increase in SUA.
Table 3 also demonstrates SUA increasing hazard ratio (HR)
in both univariate and multivariate analyses of cardiac mortality.
Variables that led to an increased HR included age, female gen-
der, diabetes mellitus, stroke, myocardial infarction, triple coronary
artery disease, and diuretic use. Nevertheless, BMI  was associated
with a decreased HR in univariate analysis. BMI, HDL cholesterol,
rtality.
Multivariate analysis
p-Value HR [exp(bi)] 95% CI p-Value
<0.001 1.10 1.02–1.19 0.020
<0.001 1.06 1.04–1.08 <0.001
<0.001 2.72 1.83–4.27 <0.001
<0.001 0.95 0.91–1.01 0.080
0.040 1.01 0.98–1.03 0.508
0.016 0.45 0.23–0.86 0.016
0.984 1.42 0.84–2.42 0.195
0.508 1.18 0.76–1.85 0.461
0.384 1.02 0.68–1.54 0.913
<0.001 1.84 1.24–2.73 0.002
0.003 1.89 1.15–3.12 0.012
0.128 1.15 0.65–2.02 0.637
<0.001 2.22 1.36–3.63 0.002
0.002 1.84 1.23–2.78 0.003
0.079 0.96 0.33–2.78 0.942
0.668 0.65 0.23–1.90 0.439
0.132 1.07 0.34–3.37 0.908
<0.001 2.26 1.51–3.41 <0.001
0.565 1.15 0.78–1.69 0.490
0.517 0.74 0.50–1.08 0.119
0.001 0.57 0.38–0.86 0.007
0.245 1.04 0.58–1.87 0.892
0.884 0.36 0.10–1.22 0.100
artery bypass grafting; ACE, angiotensin-converting enzyme.
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nd use of a beta-blocker were associated with a decreased HR in
ultivariate analysis.
iscussion
In our report, elevated SUA was predictive of cardiac and all-
ause mortality among patients with obstructive CAD deﬁned
y angiography in eastern Taiwan in a median follow-up of 3.1
ears. Over the past two decades, there were many debates for
he causal role of SUA in the development of cardiovascular
isease or all-cause death. For instance, the negative result of
ramingham Heart Study indicated that the association between
UA and cardiac and all-cause death is probably linked to other
isk factors such as hypertension, dyslipidemia, and diabetes in
he general population [18]. In contrast, SUA was  found to be a
trong predictor of cardiovascular disease mortality in 1423 healthy
iddle-aged Finnish men, independent of variables commonly
ssociated with gout or metabolic syndrome [19]. Speciﬁcally,
mong patients with angiographically proven CAD, the results
ere regionally conﬂicting. Bickel et al. demonstrated SUA as an
ndependent predictor of overall mortality in a cohort of 1017-
ersons with angiographically proven CAD after adjustment for
aseline covariates in Germany [20]; however, Tsai et al. found a
egative result in a 647-person cohort in southern Taiwan [21].
oreover, other studies revealed that elevated SUA has a prog-
ostic value in patients with severe CAD and acute myocardial
nfarction undergoing percutaneous coronary intervention as well
22,23]. Therefore, these conﬂicting results implied that the causal
ole of SUA in the pathogenesis of coronary heart disease and
elated deaths is still uncertain and needs further clinical inves-
igation.
In the ET-CHD registry, the biggest strength is that in Hualien
nd Taitung, two of the largest counties in Taiwan, totally esti-
ated 8144 km2 and with half a million people, Buddhist Tzu-Chi
eneral Hospital was the only cardiovascular referral center to
arry out coronary angiography for patients with symptomatic
AD during the study period from 1997 to 2003. In this way, the
election bias for low-risk patients with obstructive CAD could be
argely eliminated, and instead this reﬂected that there were higher
roportions of comorbidities, severe CAD, and treatment with coro-
ary bypass grafting surgery in the ET-CHD cohort than another
ngiographically deﬁned CAD study cohort in southern Taiwan
21]. In comparison with previous reports, the prognostic value of
nitial SUA levels to predict mortality seems prominent in high-
isk patients undergoing coronary interventions rather than those
eceiving medications only [22–24].
Notably, a gender difference regarding the outcomes was
resent in the study. Elevated SUA levels were highly associ-
ted with cardiac and all-cause deaths in female but not male
atients, which was consistent with the Framingham Heart Study
18] and the First National Health and Nutrition Examination Sur-
ey (NHANES I) [8,9]. The phenomenon may  be explained in part by
he fact that many metabolic abnormalities and cardiovascular dis-
ase develop in proportion to increased SUA levels after menopause
hen levels of cardiovascular protective hormones such as estro-
en gradually diminish with aging [25]. Besides, female patients
ith CAD were vulnerable to delay their ﬁrst medical treatment
ntil the development of worsening heart failure, possibly leading
o a higher risk of death than male counterparts [26]. Further-
ore, numerous studies concluded that the relationship between
UA and coronary heart disease in men  is likely to be mediated
y hypertension, use of diuretics, dyslipidaemia, or pre-existing
ardiovascular disease, but some studies have demonstrated the
elationship in women to be independent of these risk factors
9,27,28].ology 61 (2013) 122–127
A growing body of evidence suggested that SUA levels reﬂect
a status of insulin resistance syndrome [29,30]. A possible mech-
anism has been proposed that insulin enhances tubular sodium
reabsorption accompanied by increased reabsorption of UA [31].
As is known, insulin resistance is associated with hypertriglyc-
eridemia, hypertension, and inﬂammation which in turn lead to
coronary heart disease. Biologically, SUA is the main end prod-
uct of purine metabolism generated by xanthine oxidase. Under
ischemic conditions, xanthine oxidase activity and UA synthesis
are increased in vivo. In signiﬁcant obstructive CAD, hypoxia may
occur during stress, exercise, or total occlusion of diseased coronary
artery, which results in an increase in the local circulating concen-
tration of UA [32]. Therefore, elevated SUA may  act as a marker
of underlying myocardial ischemia and provides another possible
explanation for a non-causal association between hyperuricemia
and cardiovascular disease.
Finally, this study has some limitations to be addressed. First,
only 78.2% patients had complete records of all pre-set laboratory
examinations. Despite that, there was  no signiﬁcant change in all
adjusted variables after the patients with missing data were taken
into account. This reﬂects the fact that characteristics of patients
not enrolled were similar to those of patients enrolled for analysis in
the ET-CHD registry at baseline. Second, we could not adjust some
possible confounding factors at entry due to pre-existing database
such as the severity of heart failure by echocardiographic evalua-
tions and the complexity of coronary artery lesions by angiographic
SYNTAX score which was  established in 2005 [33].
In conclusion, SUA may  be a signiﬁcant predictor of cardiac and
overall mortality, independent of classic risk factors in high-risk
patients with obstructive CAD.
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